Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mikko Taalikka"'
Autor:
Markku Hillilä, Julia Tennilä, Anneli Tarpila, Anna Lyra, Sofia Männikkö, Arthur C. Ouwehand, Teppo Huttunen, Sampo J. Lahtinen, Lea Veijola, Mikko Taalikka
Publikováno v:
World Journal of Gastroenterology
AIM To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL). METHODS In this randomized triple-blind trial, adult IBS volunteers who were recruited according to Rome. criteria re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c500397967f8603689256fc9294daf8b
http://hdl.handle.net/10138/174086
http://hdl.handle.net/10138/174086
Autor:
Markku J Leskinen, Marjaana Luukkaa, Petteri Hervonen, Katariina Klintrup, Ilari Lehtinen, Tapio Utriainen, Kalevi Pulkkanen, Anna-Liisa Kautio, Mikko Taalikka, Antti Jekunen, Timo Marttila, Pirkko-Liisa Kellokumpu-Lehtinen, Vesa Kataja
Publikováno v:
Journal of Clinical Oncology. 34:e16523-e16523
e16523Background: In our Prosty I trial biweekly docetaxel (D) was better tolerated and yielded longer overall survival than standard triweekly D (Kellokumpu-Lehtinen et al. Lancet Oncol 2013;14:11...
Autor:
Mikko Taalikka, Pirkko-Liisa Kellokumpu-Lehtinen, Tapio Utriainen, Anna-Liisa Kautio, Marjaana Luukkaa, Petteri Hervonen, Vesa Kataja, Timo Marttila
Publikováno v:
Journal of Clinical Oncology. 33:276-276
276 Background: Docetaxel (D) administered at 2-week intervals was better tolerated than the standard 3-week D in mCRPC. In addition, the overall survival was better with the 2-weekly D dosing in our Prosty I trial (Kellokumpu-Lehtinen et al. Lancet
Autor:
Camilla Thellenberg-Karlsson, Lars Franzén, Mikko Taalikka, Lennart Åström, Pirkko-Liisa Kellokumpu-Lehtinen, Claes Ginman, M. Hjelm-Eriksson, Timo Marttila
Publikováno v:
Journal of Clinical Oncology. 29:63-63
63 Background: In two randomized trials a survival benefit has been shown for docetaxel (T) in metastatic, hormone refractory prostate cancer PrCa). In order to increase the recurrence-free survival and overall survival with adjuvant treatment we con